<p>Replimune Group（纳斯达克代码：REPL - 获取免费报告）预计将在 2026 年 2 月 11 日星期三市场开盘前发布其 2026 年第三季度财报。分析师预计 Replimune Group 本季度每股收益为（$0.85）。各方可以查看公司即将发布的 2026 年第三季度财报中的信息，以获取关于定于 2026 年 2 月 3 日星期二上午 8:00（东部时间）的电话会议的最新细节。</p>
<p>获取 <strong>Replimune Group</strong> 的提醒：</p>
<ul>
<li>按表现排名的最佳股票选择 AI</li>
</ul>
<p>Replimune Group（纳斯达克代码：REPL - 获取免费报告）上次于 2026 年 2 月 3 日星期二公布季度财报。该公司报告每股收益（EPS）为（$0.77），超出市场共识预期的（$0.85）$0.08。分析师平均预计 Replimune Group 在当前财年每股收益为$-3，在下一个财年每股收益也为$-3。</p>
<h2>Replimune Group 股票上涨 5.9%</h2>
<p>REPL 股票在星期三以$7.38 开盘。该公司的流动比率为 6.31，速动比率为 6.31，债务与股本比率为 0.26。该公司 50 日移动平均为$8.94，200 日移动平均为$7.22。Replimune Group 的 12 个月最低价为$2.68，最高价为$14.80。该公司的市值为 5.7889 亿美元，市盈率为-2.13，贝塔值为 0.73。</p>
<h2>Replimune Group 内部活动</h2>
<p>在 Replimune Group 的其他新闻中，董事 Kapil Dhingra 于 2025 年 12 月 9 日星期二出售了 3,169 股该股票。股票以平均价格$10.40 出售，总交易额为$32,957.60。该交易在向证券交易委员会提交的文件中披露，该文件可通过 SEC 网站访问。此外，内部人士 Christopher Sarchi 于 2025 年 11 月 17 日星期一出售了 5,208 股该公司的股票。股票以平均价格$9.10 出售，总交易额为$47,392.80。交易完成后，该内部人士直接持有 123,088 股公司股票，价值$1,120,100.80。这笔交易代表其持股比例减少了 4.06%。该交易的 SEC 文件提供了更多信息。在过去的九十天里，内部人士出售了价值$257,607 的 25,625 股公司股票。5.20% 的股票由公司内部人士持有。</p>
<h2>机构投资者对 Replimune Group 的看法</h2>
<p>一些机构投资者最近调整了对该公司的持股。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.在第一季度将其在 Replimune Group 的持股增加了 17.6%。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.现在拥有 44,352 股该公司的股票，价值$435,000，在此期间又购买了 6,653 股。Millennium Management LLC 在第一季度将其在 Replimune Group 的持股增加了 2.8%。Millennium Management LLC 现在拥有 1,223,236 股该公司的股票，价值$11,927,000，在上个季度又收购了 33,574 股。高盛集团（Goldman Sachs Group Inc.）在第一季度将其在 Replimune Group 的持股增加了 20.9%。高盛集团现在拥有 690,167 股该公司的股票，价值$6,729,000，在此期间又购买了 119,145 股。Rhumbline Advisers 在第二季度将其在 Replimune Group 的持股增加了 6.9%。Rhumbline Advisers 现在拥有 102,005 股该公司的股票，价值$948,000，在此期间又购买了 6,616 股。最后，Sei Investments Co.在第二季度将其在 Replimune Group 的持股增加了 149.5%。Sei Investments Co.现在拥有 30,478 股该公司的股票，价值$283,000，在上个季度又购买了 18,263 股。92.53% 的股票由机构投资者和对冲基金持有。</p>
<h2>分析师升级和降级</h2>
<p>几位股票研究分析师最近对该公司发表了评论。Leerink Partners 将 Replimune Group 的评级从 “市场表现” 上调至 “跑赢大盘”，并在 2025 年 10 月 20 日的报告中将其目标价从$3.00 提高至$13.00。Wedbush 将 Replimune Group 的评级从 “中性” 上调至 “跑赢大盘”，并在 2025 年 10 月 20 日的研究报告中将其目标价从$4.00 提高至$18.00。HC Wainwright 将 Replimune Group 的评级从 “中性” 上调至 “买入”，并在 2025 年 10 月 27 日的报告中设定了$12.00 的目标价。Weiss Ratings 在 2025 年 12 月 29 日的报告中重新发布了对 Replimune Group 股票的 “卖出（d-）” 评级。最后，摩根大通（JPMorgan Chase &amp; Co.）将 Replimune Group 的股票评级从 “减持” 上调至 “中性”，并在 2025 年 10 月 20 日的研究报告中设定了$11.00 的目标价。六位投资分析师对该股票给予了买入评级，两位给予了持有评级，两位给予了卖出评级。根据 MarketBeat.com，该公司的共识评级为 “持有”，平均目标价为$9.75。</p>
<p><strong>阅读我们关于 Replimune Group 的最新报告</strong></p>
<h2>关于 Replimune Group</h2>
<p>（获取免费报告）</p>
<p>Replimune Group, Inc 是一家临床阶段的生物技术公司，专注于开发下一代肿瘤溶解免疫疗法以治疗实体肿瘤。该公司的专有 “RP” 平台利用基因工程改造的单纯疱疹病毒 1 型（HSV-1）载体，携带免疫调节药物，选择性地感染、在癌细胞内复制并摧毁癌细胞，同时刺激全身抗肿瘤免疫反应。</p>
<p>Replimune 的主要候选药物 RP1，结合了 GM-CSF 和融合蛋白，以增强直接肿瘤溶解和免疫激活。</p>
<h2>进一步阅读</h2>
<ul>
<li>我们更看好的五只股票，而不是 Replimune Group</li>
<li>你的银行账户不再安全</li>
<li>雷·达里奥建议买黄金。我建议每月从中获得收入</li>
<li>每天一次，持续一小时</li>
<li>[显而易见的黄金投资]: “给我一个更好的投资。”</li>
<li>一位前 CIA 特工对即将到来的崩溃的看法</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UkVQTA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UkVQTA"/></p>
<p><em>此即时新闻提醒由叙事科学技术和来自 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 $1,000 在 Replimune Group 吗？</h2>
<p>在考虑 Replimune Group 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户在更广泛的市场注意到之前购买的股票……而 Replimune Group 并不在名单上。</p>
<p>虽然 Replimune Group 目前在分析师中被评为持有，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

IBBQ

2 倍做多纳斯达克生物技术 ETF - ProShares

动态生物技术与基因组 ETF - Invesco

医药突破 ETF - ALPS

生物科技 ETF - VanEck Vectors

标普生物技术 3 倍做空 - Direxion

REPL

纳斯达克生物科技指数 ETF - iShares Nasdaq

纽交所高增长板生物技术指数 ETF - First Trust

<p>Replimune Group（纳斯达克代码：REPL）将于 2 月 11 日发布 2026 年第三季度财报，分析师预计每股亏损 0.85 美元。该公司此前报告每股亏损 0.77 美元，超出预期。REPL 股票上涨 5.9%，开盘价为 7.38 美元。内部交易活动包括董事的股票出售，机构投资者持有 92.53% 的股份。近期分析师的评级上调显著提高了价格目标，一些公司将其评级上调至 “跑赢大盘”，目标价高达 18.00 美元</p>

<p>Replimune Group (NASDAQ:REPL - Get Free Report) is expected to be issuing its Q3 2026 results before the market opens on Wednesday, February 11th. Analysts expect Replimune Group to post earnings of ($0.85) per share for the quarter. Parties may review the information on the company's upcoming Q3 2026 earning report for the latest details on the call scheduled for Tuesday, February 3, 2026 at 8:00 AM ET.</p>
<div class="lb-trans"><p>Replimune Group（纳斯达克代码：REPL - 获取免费报告）预计将在 2026 年 2 月 11 日星期三市场开盘前发布其 2026 年第三季度财报。分析师预计 Replimune Group 本季度每股收益为（$0.85）。各方可以查看公司即将发布的 2026 年第三季度财报中的信息，以获取关于定于 2026 年 2 月 3 日星期二上午 8:00（东部时间）的电话会议的最新细节。</p>
</div><p>Get <strong>Replimune Group</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Replimune Group</strong> 的提醒：</p>
</div><ul>
<li>The Best AI for Picking Stocks, Ranked by Performance</li>
</ul>
<div class="lb-trans"><ul>
<li>按表现排名的最佳股票选择 AI</li>
</ul>
</div><p>Replimune Group (NASDAQ:REPL - Get Free Report) last announced its quarterly earnings data on Tuesday, February 3rd. The company reported ($0.77) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.85) by $0.08. On average, analysts expect Replimune Group to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.</p>
<div class="lb-trans"><p>Replimune Group（纳斯达克代码：REPL - 获取免费报告）上次于 2026 年 2 月 3 日星期二公布季度财报。该公司报告每股收益（EPS）为（$0.77），超出市场共识预期的（$0.85）$0.08。分析师平均预计 Replimune Group 在当前财年每股收益为$-3，在下一个财年每股收益也为$-3。</p>
</div><h2>Replimune Group Stock Up 5.9%</h2>
<div class="lb-trans"><h2>Replimune Group 股票上涨 5.9%</h2>
</div><p>REPL stock opened at $7.38 on Wednesday. The company has a current ratio of 6.31, a quick ratio of 6.31 and a debt-to-equity ratio of 0.26. The firm has a 50-day moving average of $8.94 and a two-hundred day moving average of $7.22. Replimune Group has a 12 month low of $2.68 and a 12 month high of $14.80. The company has a market cap of $578.89 million, a price-to-earnings ratio of -2.13 and a beta of 0.73.</p>
<div class="lb-trans"><p>REPL 股票在星期三以$7.38 开盘。该公司的流动比率为 6.31，速动比率为 6.31，债务与股本比率为 0.26。该公司 50 日移动平均为$8.94，200 日移动平均为$7.22。Replimune Group 的 12 个月最低价为$2.68，最高价为$14.80。该公司的市值为 5.7889 亿美元，市盈率为-2.13，贝塔值为 0.73。</p>
</div><h2>Insider Activity at Replimune Group</h2>
<div class="lb-trans"><h2>Replimune Group 内部活动</h2>
</div><p>In other Replimune Group news, Director Kapil Dhingra sold 3,169 shares of the stock in a transaction dated Tuesday, December 9th. The shares were sold at an average price of $10.40, for a total transaction of $32,957.60. The sale was disclosed in a document filed with the Securities &amp; Exchange Commission, which is accessible through the SEC website. Also, insider Christopher Sarchi sold 5,208 shares of the business's stock in a transaction that occurred on Monday, November 17th. The shares were sold at an average price of $9.10, for a total transaction of $47,392.80. Following the completion of the sale, the insider directly owned 123,088 shares in the company, valued at $1,120,100.80. This trade represents a 4.06% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 25,625 shares of company stock worth $257,607. 5.20% of the stock is owned by corporate insiders.</p>
<div class="lb-trans"><p>在 Replimune Group 的其他新闻中，董事 Kapil Dhingra 于 2025 年 12 月 9 日星期二出售了 3,169 股该股票。股票以平均价格$10.40 出售，总交易额为$32,957.60。该交易在向证券交易委员会提交的文件中披露，该文件可通过 SEC 网站访问。此外，内部人士 Christopher Sarchi 于 2025 年 11 月 17 日星期一出售了 5,208 股该公司的股票。股票以平均价格$9.10 出售，总交易额为$47,392.80。交易完成后，该内部人士直接持有 123,088 股公司股票，价值$1,120,100.80。这笔交易代表其持股比例减少了 4.06%。该交易的 SEC 文件提供了更多信息。在过去的九十天里，内部人士出售了价值$257,607 的 25,625 股公司股票。5.20% 的股票由公司内部人士持有。</p>
</div><h2>Institutional Investors Weigh In On Replimune Group</h2>
<div class="lb-trans"><h2>机构投资者对 Replimune Group 的看法</h2>
</div><p>A number of institutional investors have recently modified their holdings of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of Replimune Group by 17.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 44,352 shares of the company's stock valued at $435,000 after buying an additional 6,653 shares during the period. Millennium Management LLC grew its position in Replimune Group by 2.8% in the 1st quarter. Millennium Management LLC now owns 1,223,236 shares of the company's stock valued at $11,927,000 after acquiring an additional 33,574 shares in the last quarter. Goldman Sachs Group Inc. increased its stake in Replimune Group by 20.9% during the first quarter. Goldman Sachs Group Inc. now owns 690,167 shares of the company's stock worth $6,729,000 after purchasing an additional 119,145 shares during the period. Rhumbline Advisers increased its stake in Replimune Group by 6.9% during the second quarter. Rhumbline Advisers now owns 102,005 shares of the company's stock worth $948,000 after purchasing an additional 6,616 shares during the period. Finally, Sei Investments Co. lifted its position in shares of Replimune Group by 149.5% during the second quarter. Sei Investments Co. now owns 30,478 shares of the company's stock worth $283,000 after purchasing an additional 18,263 shares in the last quarter. 92.53% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>一些机构投资者最近调整了对该公司的持股。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.在第一季度将其在 Replimune Group 的持股增加了 17.6%。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.现在拥有 44,352 股该公司的股票，价值$435,000，在此期间又购买了 6,653 股。Millennium Management LLC 在第一季度将其在 Replimune Group 的持股增加了 2.8%。Millennium Management LLC 现在拥有 1,223,236 股该公司的股票，价值$11,927,000，在上个季度又收购了 33,574 股。高盛集团（Goldman Sachs Group Inc.）在第一季度将其在 Replimune Group 的持股增加了 20.9%。高盛集团现在拥有 690,167 股该公司的股票，价值$6,729,000，在此期间又购买了 119,145 股。Rhumbline Advisers 在第二季度将其在 Replimune Group 的持股增加了 6.9%。Rhumbline Advisers 现在拥有 102,005 股该公司的股票，价值$948,000，在此期间又购买了 6,616 股。最后，Sei Investments Co.在第二季度将其在 Replimune Group 的持股增加了 149.5%。Sei Investments Co.现在拥有 30,478 股该公司的股票，价值$283,000，在上个季度又购买了 18,263 股。92.53% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师升级和降级</h2>
</div><p>Several equities research analysts recently commented on the company. Leerink Partners raised Replimune Group from a &#34;market perform&#34; rating to an &#34;outperform&#34; rating and increased their price target for the company from $3.00 to $13.00 in a report on Monday, October 20th. Wedbush raised Replimune Group from a &#34;neutral&#34; rating to an &#34;outperform&#34; rating and raised their target price for the stock from $4.00 to $18.00 in a research note on Monday, October 20th. HC Wainwright upgraded Replimune Group from a &#34;neutral&#34; rating to a &#34;buy&#34; rating and set a $12.00 price target on the stock in a report on Monday, October 27th. Weiss Ratings reissued a &#34;sell (d-)&#34; rating on shares of Replimune Group in a report on Monday, December 29th. Finally, JPMorgan Chase &amp; Co. upgraded shares of Replimune Group from an &#34;underweight&#34; rating to a &#34;neutral&#34; rating and set a $11.00 price objective for the company in a research report on Monday, October 20th. Six investment analysts have rated the stock with a Buy rating, two have given a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of &#34;Hold&#34; and an average target price of $9.75.</p>
<div class="lb-trans"><p>几位股票研究分析师最近对该公司发表了评论。Leerink Partners 将 Replimune Group 的评级从 “市场表现” 上调至 “跑赢大盘”，并在 2025 年 10 月 20 日的报告中将其目标价从$3.00 提高至$13.00。Wedbush 将 Replimune Group 的评级从 “中性” 上调至 “跑赢大盘”，并在 2025 年 10 月 20 日的研究报告中将其目标价从$4.00 提高至$18.00。HC Wainwright 将 Replimune Group 的评级从 “中性” 上调至 “买入”，并在 2025 年 10 月 27 日的报告中设定了$12.00 的目标价。Weiss Ratings 在 2025 年 12 月 29 日的报告中重新发布了对 Replimune Group 股票的 “卖出（d-）” 评级。最后，摩根大通（JPMorgan Chase &amp; Co.）将 Replimune Group 的股票评级从 “减持” 上调至 “中性”，并在 2025 年 10 月 20 日的研究报告中设定了$11.00 的目标价。六位投资分析师对该股票给予了买入评级，两位给予了持有评级，两位给予了卖出评级。根据 MarketBeat.com，该公司的共识评级为 “持有”，平均目标价为$9.75。</p>
</div><p><strong>Read Our Latest Report on Replimune Group</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 Replimune Group 的最新报告</strong></p>
</div><h2>About Replimune Group</h2>
<div class="lb-trans"><h2>关于 Replimune Group</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company's proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.</p>
<div class="lb-trans"><p>Replimune Group, Inc 是一家临床阶段的生物技术公司，专注于开发下一代肿瘤溶解免疫疗法以治疗实体肿瘤。该公司的专有 “RP” 平台利用基因工程改造的单纯疱疹病毒 1 型（HSV-1）载体，携带免疫调节药物，选择性地感染、在癌细胞内复制并摧毁癌细胞，同时刺激全身抗肿瘤免疫反应。</p>
</div><p>Replimune's lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.</p>
<div class="lb-trans"><p>Replimune 的主要候选药物 RP1，结合了 GM-CSF 和融合蛋白，以增强直接肿瘤溶解和免疫激活。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than Replimune Group</li>
<li>Your Bank Account Is No Longer Safe</li>
<li>Ray Dalio Says Buy Gold. I Say Get Paid Every Month From It</li>
<li>1 Hour Once A Day</li>
<li>[No Brainer Gold Play]: “Show me a better investment.”</li>
<li>What a Former CIA Agent Knows About the Coming Collapse</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，而不是 Replimune Group</li>
<li>你的银行账户不再安全</li>
<li>雷·达里奥建议买黄金。我建议每月从中获得收入</li>
<li>每天一次，持续一小时</li>
<li>[显而易见的黄金投资]: “给我一个更好的投资。”</li>
<li>一位前 CIA 特工对即将到来的崩溃的看法</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UkVQTA" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=REPL"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和来自 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Replimune Group Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 $1,000 在 Replimune Group 吗？</h2>
</div><p>Before you consider Replimune Group, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Replimune Group 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Replimune Group wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户在更广泛的市场注意到之前购买的股票……而 Replimune Group 并不在名单上。</p>
</div><p>While Replimune Group currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Replimune Group 目前在分析师中被评为持有，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Replimune Group (REPL) 将在周三公布季度收益